Exane BNP Paribas Downgrades GlaxoSmithKline (GSK) to Underperform
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $51.15 +1.73%
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
6 Buy, 16 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Exane BNP Paribas downgraded GlaxoSmithKline (NYSE: GSK) from Outperform to Underperform.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $47.11 yesterday.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $47.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Flexsteel (FLXS) to Hold
- KeyBanc Downgrades Kite Realty Group (KRG) to Sector Weight
- Piper Sandler Downgrades Weave Communications Inc (WEAV) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
